MUMBAI, India, Jan. 12, 2022 /PRNewswire/ -- Alkem Laboratories Ltd. (Alkem) hereby announces to launch a unique patented technology  for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on  disruptive  4D  Bioprinting  technology,  which  would  be  used  to  treat  deep,  non-healing  chronic  wounds and is expected to be launched in the Indian market in the latter half of 2022 post  regulatory approval. This advanced technology for DFU management has a high scope of  preventing amputations in diabetic patients. This technology will be available at affordable  rates  to Indian  patients  at a  time  when  there  is  no  definitive  treatment  for  DFU  in  India.

India currently has approximately 77 mn diabetes patients, the second highest in the world.  A diabetic foot ulcer is one of the most significant and devastating complications of diabetes  and is defined as a foot affected by ulceration that is associated with neuropathy and/or  peripheral arterial disease of the lower limb in a patient with diabetes. Approximately, 12-15% with diabetes suffer from DFU at least once in a lifetime. 5–24% of them will finally lead  to limb amputation within 6–18 months after the first evaluation. The risk of foot  ulceration and limb amputation increases with age and the duration of diabetes. Alkem has  collaborated with Rokit Healthcare Inc. to commercialize the technology in India to help  reduce amputation amongst DFU patients considering the negative impact of amputation on  a  patient's  quality  of life  and  the associated  economic  burden  on  the  healthcare  system.

Mr. Sandeep Singh, Managing Director, Alkem Laboratories Ltd., stated, "In India, Diabetes  is one of the major healthcare challenges. The challenge in itself is so huge that diabetic foot  ulcers often get ignored. Approximately 1 lac people have to undergo amputation every year  and  compromise  on  their  quality  of  life.  To  address  the  problem,  Alkem  has  collaborated  with  Rokit Healthcare Inc., a global regenerative solutions company, to bring out novel solutions  for  the  management  of  diabetic  foot  ulcers."

Adding further, Mr. Sandeep asserted, "Alkem, over the years, has always been at the  forefront in delivering high-quality patient care, through its innovation and patient-centric  initiatives."

About  Alkem  Laboratories  Ltd.:

Established  in  1973  and  headquartered  in  Mumbai,  Alkem  (NSE:  ALKEM,  BSE:  539523) is a leading Indian pharmaceutical company with global  operations, engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical  products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients  (APIs), and nutraceuticals, which it markets in India and International markets. With a portfolio of  more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in  terms  of  domestic  sales  (Source:  IQVIA  March  2021).  The  Company  also  has  presence  in  more  than  40  international  markets, with  the  United States  being  its  key  focus  market.

For  more  information  on  Alkem  Laboratories  Ltd.,  please  visit  www.alkemlabs.com